Volume has been off the charts on a sustained basis and the price has been relatively controlled. People are loading up for the next leg up ... JMHO
Well, Keep did advise me to try milking them on my head to relieve boredom, but now I'm bored with that, too, so I'll just have the "help" do it for me! ;-)
The indexes don't really affect ACTC as it is not included in any of them. But, I concede that overall sentiment might be calling for some profit taking in them.
Well, karl ... I've been in this stock for about 4 years ... don't visit this board regularly as it was a wasteland. Not sure if anybody else posted that sentiment, it was spontaneous and off the top of my head.
Like clockwork ... where were your Eeyore prognostications when this ran up to $9.40 this a.m.? Oh, you were afraid it was the real deal and not just a trial run, so you waited for the predictable pull back to start with your gloom and doom again?
Oh, and don't waste your breath about "the cows", Keep! I've got "help" to do that!
Yeah, dem, you're right. A "big" can margin or play most anything. Was thinking more retail, I guess. I just know I've missed out over the years on some big $$ by trading too much when I bought "right" in the first place. So, while tempting, I'm just holding my shares and adding on dips when given the opportunity. This a.m.'s dip was one of them. Sitting on more shares of this than in the past ... but most were bought quite a bit lower, so I'm in a good place for now. Cash is a good thing, Dem! I'm sure you will put it to work when you see fit!
I just don't think a person can time this, anymore. The lower float makes it a lot harder to jump in on good news. I used to trade it some, but, I'm just holding on now, come hell or high water! Margin buying isn't a factor here (yet) since it's not marginable.
Food for thought:
Here are nine surprising things Jesse Livermore said regarding excessive trading:
1. “Money is made by sitting, not trading.”
2. “It takes time to make money.”
3. “It was never my thinking that made the big money for me, it always was sitting.”
4. “Nobody can catch all the fluctuations.”
5. “The desire for constant action irrespective of underlying conditions is responsible for many losses in Wall Street even among the professionals, who feel that they must take home some money everyday, as though they were working for regular wages.”
6. “Buy right, sit tight.”
7. “Men who can both be right and sit tight are uncommon.”
8. “Don’t give me timing, give me time.”
and finally, the most important thing:
9. “There is a time for all things, but I didn’t know it. And that is precisely what beats so many men in Wall Street who are very far from being in the main sucker class. There is the plain fool, who does the wrong thing at all times everywhere, but there is the Wall Street fool, who thinks he must trade all the time. Not many can always have adequate reasons for buying and selling stocks daily – or sufficient knowledge to make his play an intelligent play.”
The stars are aligning, FINALLY. Sit back and watch the show!! Don't be swayed by the price gyrations, pumpers/bashers ... you're in on the ground floor of a paradigm shift! How you got here doesn't really matter ... just keep hanging on to this teams' coattails for the ride of your life!!
You guys did discuss the fact that GE is opening a "facility" less than 2 miles from ACTC in 2015, right? I don't recall if I saw it being talked about here or not! Their Life Sciences division will be involved, I'll bet cha!!
Here is an example of FDA moving a little faster ... sounds like our P1 trial, and soon to be P2.
Merck began testing the drug in humans in 2011 in what is known as a phase 1 study. Such studies are typically conducted in a small group of patients to test whether a drug is safe. Usually, two additional phases of studies—with larger patient populations—are needed to demonstrate a drug's efficacy and safety before the FDA will consider approving it, but sometimes the agency approves cancer drugs based on early- to midstage trials.
Dr. Ribas said he started to notice positive results relatively soon after he began overseeing pembrolizumab's testing in melanoma patients. The phase 1 study also included patients with other tumor types such as lung cancer. Merck made the unusual decision to expand and continue the phase 1 study, which eventually grew to more than 1,100 patients of various tumor types, believed to the biggest phase 1 cancer study ever.
One study participant, 59-year-old Kathleen Thomas of Redondo Beach, Calif., said she felt like she'd been given a "death sentence" when she was diagnosed with advanced melanoma in April 2011.
Her disease progressed after treatment with surgeries and drugs including Yervoy. She lost weight and strength, forcing her to use a wheelchair. Within months of joining the pembrolizumab trial in late 2012, Ms. Thomas said she began to feel better, regaining weight and using the wheelchair less often. Imaging scans have shown that her tumors have either shrunk, disappeared or remained stable, she said.
Patient interest in the Merck drug and other immunotherapies has given rise to petition drives and social-media campaigns seeking access to the drugs before regulators had approved them for sale. Such demand has fueled legislation in some states that gives terminally ill patients a "right to try" certain experimental drugs without having to go through an FDA program for early access, if a drug's manufacturer is willing. Me
Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office (USPTO) has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
“The addition of this new patent continues to strengthen our IP position around core cell therapy components and helps protect our leading position in the regenerative medicine field,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “It is an exciting time to be here as we concentrate our efforts on developing cures for diseases and disorders of the eye and get ready to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD).”
Because the "good doctor" has been implementing these planned sales regularly for years. His stock is compensation and taxes are due on it. The guy also has living expenses. But, most of all, a planned sale is executed six months after the plan is put in place by a third party acting as his fiduciary agent. It is irrelevant and I suspect he knows more shares will replenish his stash!!
Stick to bashing ... math is clearly not your forte! It's NOT $623,317.00!!
And, just for the record, although I assume you knew this: it is a "Planned Sale" meaning arranged ahead of time so as not to conflict with any material news/event that is known to the seller. It is handled by a third-party and is PRE-arranged! How else is the man supposed to pay Uncle Sam when his compensation is stock based?
We ALL know what a 10b5-1 Planned Sale is ...
Form 4 just filed for Dr. L!!
PLANNED sale is the operative word here!!! The guy's gotta eat, too!!
Partnering is the way to go. We're in the same sweet spot that REGN was a few short years ago!
IN SOME CASES, SMALLER biotechnology companies gain stability from key partnerships. Kaul bought another one of his top holdings, Regeneron Pharmaceuticals (REGN) in the summer of 2010, when it was trading below $40 a share, prior to the launch of its macular-degeneration treatment, Eylea. Wall Street's expectations were low—it now trades at $253—as many investors didn't understand the value of Regeneron's partnership with Paris-based health-care giant Sanofi (SAN.France). "Because that research was funded by Sanofi, it really mitigated the downside," says Kaul.
And, believe it or not ... holding a ton of ACTC awaiting TLD announcement any time now. THAT is my "pie in the sky, make me rich someday" gem! lol
Hey guys ... keep your eye on ACTCD! Just did a reverse split (had planned it but sprung it out of the blue) and announced some real high fliers in the biotech world to their Scientific Advisory Board right on the R/S's heels. Market responded very favorably! And, now we're in wait mode for uplisting and release of ITLD. Just passing it on ... not pumping!